National Research Center for Hematology
National Research Center for Hematology
Moscow, Moscow, Russia1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | mediastinal malignant lymphoma | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06188676 |